zovegalisib Updated Nov 6
The ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.
- Zovegalisib's mutant-selective allosteric mechanism is differentiated from approved PI3K-alpha inhibitors (alpelisib, inavolisib) and could offer better tolerability, especially less hyperglycemia, which has been a major limitation of the class.
- Phase 1/2 ReDiscover data showed a 43% ORR and median 11.1-month PFS in heavily pre-treated patients, with FDA Breakthrough Therapy Designation validating the approach.
- Massive institutional accumulation in Q2 2026: FMR LLC doubled to $376M, BlackRock $286M, State Street $189M, T. Rowe Price $144M, and new positions from Baker Bros., Westfield Capital, and Polar Capital.
- Zovegalisib is still unapproved and faces a long development timeline; Phase 3 ReDiscover-2 enrollment completes mid-2027, with pivotal data likely in 2028 or later.
- Competition is entrenched: alpelisib (Novartis), inavolisib (Roche), and capivasertib (AstraZeneca) are already approved in the same or overlapping indications.
- Insider selling is notable: CEO Sanjiv Patel sold $872K in October and $913K in September, and a 6M-share block was sold by SVF Pauling in August.